Ken Griffin Caribou Biosciences, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Caribou Biosciences, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 20,500 shares of CRBU stock, worth $33,620. This represents 0.0% of its overall portfolio holdings.
Number of Shares
20,500
Previous 25,900
20.85%
Holding current value
$33,620
Previous $148,000
29.05%
% of portfolio
0.0%
Previous 0.0%
Shares
6 transactions
Others Institutions Holding CRBU
# of Institutions
158Shares Held
67.4MCall Options Held
111KPut Options Held
105K-
Black Rock Inc. New York, NY7.01MShares$11.5 Million0.0% of portfolio
-
Pfm Health Sciences, LP San Francisco, CA6.48MShares$10.6 Million1.64% of portfolio
-
State Street Corp Boston, MA6.35MShares$10.4 Million0.0% of portfolio
-
Avidity Partners Management LP Dallas, TX5.79MShares$9.49 Million1.15% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.11MShares$6.74 Million0.0% of portfolio
About Caribou Biosciences, Inc.
- Ticker CRBU
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,840,800
- Market Cap $99.8M
- Description
- Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...